首页> 美国卫生研究院文献>Cancer Biology Therapy >Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells
【2h】

Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells

机译:鉴定西曲溴铵和伊立替康为对NDRG1缺陷型前列腺癌细胞具有合成杀伤力的化合物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The N-myc downstream regulated gene 1 (NDRG1) has been identified as a metastasis-suppressor gene in prostate cancer (PCa). Compounds targeting PCa cells deficient in NDRG1 could potentially decrease invasion/metastasis of PCa. A cell based screening strategy was employed to identify small molecules that selectively target NDRG1 deficient PCa cells. DU-145 PCa cells rendered deficient in NDRG1 expression by a lentiviral shRNA-mediated knockdown strategy were used in the primary screen. Compounds filtered from the primary screen were further validated through proliferation and clonogenic survival assays in parental and NDRG1 knockdown PCa cells. Screening of 3360 compounds revealed irinotecan and cetrimonium bromide (CTAB) as compounds that exhibited synthetic lethality against NDRG1 deficient PCa cells. A three-dimensional (3-D) invasion assay was utilized to test the ability of CTAB to inhibit invasion of DU-145 cells. CTAB was found to remarkably decrease invasion of DU-145 cells in collagen matrix. Our results suggest that CTAB and irinotecan could be further explored for their potential clinical benefit in patients with NDRG1 deficient PCa.
机译:N-myc下游调控基因1(NDRG1)已被确定为前列腺癌(PCa)的转移抑制基因。针对缺乏NDRG1的PCa细胞的化合物可能会降低PCa的侵袭/转移。采用基于细胞的筛选策略来鉴定选择性靶向NDRG1缺陷型PCa细胞的小分子。在初筛中使用了通过慢病毒shRNA介导的敲低策略使NDRG1表达缺失的DU-145 PCa细胞。通过亲本和NDRG1抑制的PCa细胞的增殖和克隆形成存活分析进一步验证了从初筛筛选出的化合物。对3360种化合物的筛选显示,伊立替康和溴化西曲铵(CTAB)为对NDRG1缺陷型PCa细胞表现出合成杀伤力的化合物。利用三维(3-D)入侵试验来测试CTAB抑制DU-145细胞入侵的能力。发现CTAB显着减少了胶原基质中DU-145细胞的侵袭。我们的结果表明,对于患有NDRG1缺乏症的PCa患者,CTAB和伊立替康具有潜在的临床价值,可以进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号